Dr. Raphael Bueno

--- Page Content ---

Dr. Raphael Bueno, MD
Leader of Mesothelioma Genomic Research
Position	Chief of Thoracic Surgery
Institution	Brigham and Women's Hospital
Program Led	International Mesothelioma Program
Research Focus	Genomics & Personalized Medicine
Key Discoveries	BAP1, CDKN2A, RHOA mutations
Succeeded	Dr. David Sugarbaker (2018)
Free Case Review →

Executive Summary

Dr. Raphael Bueno serves as Chief of Thoracic Surgery at Brigham and Women's Hospital and leads the International Mesothelioma Program (IMP), the world's largest mesothelioma research and treatment initiative. Following Dr. David Sugarbaker's death in 2018, Dr. Bueno assumed leadership of the program and has pioneered research into the genomic and molecular basis of mesothelioma. His research team conducted groundbreaking whole-genome sequencing studies that identified critical gene mutations affecting disease progression and treatment response, including BAP1, CDKN2A, MYH9, and RHOA. These discoveries have opened pathways for developing targeted therapies that address specific genetic abnormalities in mesothelioma cells. Under Dr. Bueno's direction, the IMP continues advancing personalized medicine approaches, utilizing tumor tissue banks and genomic profiling to match patients with optimal treatment strategies.

The genomic discoveries emerging from Dr. Bueno's laboratory have transformed understanding of why mesothelioma responds differently in different patients. The BAP1 gene, mutated in 44-60% of mesotheliomas, plays a critical role in DNA repair and cell cycle regulation; patients with BAP1 mutations often have better prognoses than those without. Conversely, CDKN2A deletions—more common in male patients—correlate with shorter survival times. These insights enable oncologists to better predict outcomes and select appropriate treatment intensities.

Beyond research, Dr. Bueno maintains an active surgical practice, performing complex mesothelioma operations while training the next generation of thoracic surgeons. The IMP's tumor tissue bank, built over decades of surgical cases, provides an invaluable resource for ongoing research into mesothelioma biology. His team is currently investigating combinations of immunotherapy with targeted agents, seeking to build on the success of the CheckMate 743 trial while addressing the specific genetic vulnerabilities identified through genomic profiling.

At a Glance

• Largest mesothelioma research program globally — Leads the International Mesothelioma Program at Brigham and Women's Hospital, the world's most comprehensive mesothelioma initiative
• Pioneered genomic profiling for mesothelioma — His team conducted the first whole-genome sequencing of mesothelioma tumors, revealing mutations that now guide treatment decisions
• Identified BAP1 as a survival predictor — Patients with BAP1 mutations tend to live longer, enabling oncologists to tailor treatment intensity to each patient's genetic profile
• Uncovered gender-linked mutation patterns — Discovered that CDKN2A deletions occur more often in men and correlate with shorter survival, informing gender-specific treatment planning
• Expanded the targeted therapy pipeline — His MYH9 and RHOA mutation discoveries have opened entirely new drug targets that did not exist before his research
• Builds on a legendary surgical legacy — Succeeded Dr. David Sugarbaker in 2018, maintaining aggressive surgical traditions while adding cutting-edge genomic capabilities
• Matches patients to optimal treatments — Every IMP patient receives comprehensive genomic profiling, ensuring treatment plans reflect individual tumor biology rather than one-size-fits-all protocols
• Advances immunotherapy combinations — Currently testing checkpoint inhibitors alongside targeted agents to exploit the specific genetic weaknesses his team has identified in mesothelioma cells

Key Facts

Metric	Finding
Current Position	Chief of Thoracic Surgery, Brigham and Women's Hospital
Program Leadership	Director, International Mesothelioma Program (since 2018)
Research Focus	Genomic and molecular basis of mesothelioma
Key Method	Whole-genome sequencing of mesothelioma tumors
BAP1 Discovery	Identified BAP1 mutations in 44-60% of mesotheliomas
CDKN2A Finding	Men more likely to have CDKN2A deletions (correlates with lower survival)
Additional Mutations	MYH9 and RHOA genes reduce survival regardless of gender
Approach	Personalized medicine matching patients to optimal treatments
Resources	Tumor tissue banks and genomic profiling capabilities
Clinical Trials	Novel combinations of immunotherapy, targeted agents, and traditional treatments

Who Is Dr. Raphael Bueno and How Did He Assume Leadership of the IMP?

Dr. Raphael Bueno is a thoracic surgeon and researcher who has dedicated his career to understanding the molecular underpinnings of thoracic malignancies, particularly mesothelioma. When Dr. David Sugarbaker passed away in August 2018, Dr. Bueno was the natural successor to lead the International Mesothelioma Program—the world's preeminent mesothelioma research center that Sugarbaker had founded in 2002.

Dr. Bueno's transition to program leadership represented both continuity and evolution. While maintaining the IMP's commitment to aggressive multimodal treatment for appropriate patients, he expanded the program's focus on genomic research and personalized medicine approaches.

"Dr. Bueno represents the next generation of mesothelioma research—building on Dr. Sugarbaker's surgical legacy while adding the genomic understanding that will drive future breakthroughs. His work identifying specific gene mutations is already helping match patients with the treatments most likely to work for their particular cancer."

— Paul Danziger, Founding Partner, Danziger & De Llano

What Genomic Discoveries Has Dr. Bueno Made?

Dr. Bueno's research team conducted groundbreaking whole-genome sequencing studies on mesothelioma tumors, identifying critical gene mutations that affect disease progression and treatment response.

BAP1 Mutations

BAP1 (BRCA1-associated protein 1) is a tumor suppressor gene mutated in approximately 44-60% of mesotheliomas. Dr. Bueno's research has revealed:

• BAP1 loss impairs DNA repair mechanisms
• BAP1-mutated tumors may be more sensitive to certain treatments
• Germline BAP1 mutations indicate hereditary cancer susceptibility
• BAP1 status serves as both a prognostic and potential therapeutic marker

ℹ️ BAP1 Cancer Syndrome: Some families carry inherited BAP1 mutations that increase risk for mesothelioma and other cancers. Dr. Bueno's research has contributed to understanding this syndrome and developing guidelines for genetic counseling.

CDKN2A Deletions

Dr. Bueno's work revealed that men with mesothelioma are more likely to experience CDKN2A gene deletions, which correlate with lower survival rates. This finding has important implications:

• CDKN2A deletions indicate more aggressive disease
• Patients with this deletion may need more intensive treatment
• Testing for CDKN2A status helps predict prognosis
• CDK4/6 inhibitors may potentially restore normal cell cycle control

MYH9 and RHOA Mutations

The research team also identified mutations in MYH9 and RHOA genes that reduce survival regardless of gender. These discoveries have:

• Expanded understanding of mesothelioma biology
• Identified potential new therapeutic targets
• Improved prognostic accuracy
• Opened pathways for developing targeted therapies

Gene	Mutation Frequency	Clinical Impact
BAP1	44-60%	May predict sensitivity to platinum chemotherapy, PARP inhibitors
CDKN2A	Variable (higher in men)	Associated with worse prognosis, potential CDK inhibitor target
MYH9	Present in subset	Reduces survival, emerging therapeutic target
RHOA	Present in subset	Reduces survival, emerging therapeutic target

How Is Dr. Bueno Advancing Personalized Medicine?

Under Dr. Bueno's direction, the IMP continues to advance personalized medicine approaches that match individual patients with their optimal treatment strategies.

Tumor Tissue Banks

The IMP maintains extensive tumor tissue banks collected over decades. These samples enable:

• Genomic sequencing of historical and current tumors
• Comparison of genetic profiles with treatment outcomes
• Identification of mutations that predict treatment response
• Development of new therapeutic targets

Genomic Profiling

Every patient at the IMP receives comprehensive genomic profiling, including:

• Whole-genome or targeted sequencing
• Analysis of known mesothelioma mutations
• Identification of potential therapeutic targets
• Assessment of prognosis based on genetic markers

"Personalized medicine is the future of mesothelioma treatment. Dr. Bueno's work means that treatment decisions are increasingly based on what's happening in each patient's specific tumor—not just what works for mesothelioma in general. That's how we'll continue improving outcomes."

— Rod De Llano, Founding Partner, Danziger & De Llano

What Clinical Trials Is the IMP Conducting Under Dr. Bueno?

Dr. Bueno's research group participates in numerous clinical trials exploring novel combinations of immunotherapy, targeted agents, and traditional treatments.

Areas of Active Research:

• Immunotherapy Combinations: Testing checkpoint inhibitors with other agents
• Targeted Therapies: Drugs designed for specific genetic mutations
• Biomarker Development: Identifying predictors of treatment response
• Surgical Timing: Optimal sequencing of surgery with systemic therapy
• Perioperative Immunotherapy: Immunotherapy before and after surgery

✅ Clinical Trial Access: Patients treated at the IMP have access to clinical trials testing cutting-edge treatments not available elsewhere. This includes trials specifically designed for patients with certain genetic mutations identified through genomic profiling.

How Does the International Mesothelioma Program Continue Sugarbaker's Legacy?

Under Dr. Bueno's leadership, the IMP maintains its position as the world's largest and most comprehensive mesothelioma research and treatment initiative:

Continuing Traditions:

• Multidisciplinary collaboration across five Boston institutions
• Commitment to aggressive treatment for appropriate candidates
• Comprehensive surgical expertise (both P/D and EPP)
• Training the next generation of mesothelioma specialists

New Directions Under Bueno:

• Enhanced focus on genomic research
• Personalized medicine approaches
• Integration of immunotherapy with traditional treatments
• Liquid biopsy and ctDNA monitoring

The IMP continues to collaborate with Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Boston VA Health Care System, and Harvard School of Public Health.

What Is the Future of Mesothelioma Research Under Dr. Bueno?

Dr. Bueno's research agenda points toward several frontiers in mesothelioma treatment:

Near-Term Goals:

• Validate genomic biomarkers for treatment selection
• Identify patients who will respond to immunotherapy
• Develop targeted therapies for specific mutations
• Optimize combination treatment sequences

Long-Term Vision:

• Cure some patients with early-stage disease
• Convert mesothelioma to a chronic, manageable condition
• Prevent mesothelioma in high-risk individuals
• Eliminate asbestos-related disease through prevention and treatment

"The genomic research Dr. Bueno is leading will fundamentally change how we treat mesothelioma. When we can look at a patient's tumor and know which treatment will work best for their specific cancer, outcomes will improve dramatically. That's the promise of personalized medicine."

— David Foster, Client Advocate, Danziger & De Llano

Frequently Asked Questions

What makes Dr. Bueno's genomic research different from other mesothelioma research?

Dr. Bueno's team conducted the first comprehensive whole-genome sequencing of mesothelioma tumors, identifying gene mutations that directly influence how patients respond to treatment. This approach moves beyond treating mesothelioma as a single disease and instead targets the specific genetic abnormalities driving each patient's cancer.

How does BAP1 mutation status affect a mesothelioma patient's outlook?

Patients whose tumors carry BAP1 mutations tend to have a better prognosis than those without the mutation. BAP1 status also helps oncologists determine which treatments may be most effective, since BAP1-mutated tumors may respond differently to platinum-based chemotherapy and emerging targeted therapies.

Can patients outside Boston access the International Mesothelioma Program?

Yes. The IMP at Brigham and Women's Hospital accepts patients from across the United States and internationally. Many patients travel to Boston specifically for the program's expertise in genomic profiling and access to clinical trials that are not available at other institutions.

What is the role of genomic profiling in mesothelioma treatment decisions?

Genomic profiling analyzes the DNA of a patient's tumor to identify specific mutations such as BAP1, CDKN2A, MYH9, and RHOA. The results help oncologists select therapies that target those mutations directly, predict how aggressive the cancer may be, and determine eligibility for targeted clinical trials.

How did Dr. Bueno continue Dr. Sugarbaker's work after 2018?

Dr. Bueno preserved the IMP's commitment to aggressive multimodal treatment and its multidisciplinary collaboration across five Boston institutions. He expanded the program's focus on genomic research and personalized medicine, adding capabilities like whole-genome sequencing and liquid biopsy monitoring that did not exist during Sugarbaker's tenure.

What types of clinical trials does the IMP offer under Dr. Bueno?

The IMP conducts trials testing immunotherapy combinations, targeted therapies designed for specific gene mutations, biomarker-driven treatment selection, and perioperative immunotherapy protocols. Some trials are specifically designed for patients whose genomic profiling reveals particular mutations identified by Dr. Bueno's research.

Does Dr. Bueno's research apply to all types of mesothelioma?

While much of Dr. Bueno's published genomic research has focused on pleural mesothelioma (the most common type), the mutation patterns he identified—including BAP1 and CDKN2A—are also relevant to peritoneal and other mesothelioma subtypes. The IMP treats patients with all forms of the disease.

Quick Statistics

• BAP1 mutation prevalence: Found in approximately 44-60% of all mesothelioma tumors analyzed
• IMP collaboration: Five Boston-area institutions contribute to the program's research and clinical work
• Tumor tissue bank: Decades of archived surgical specimens supporting ongoing genomic studies
• Whole-genome sequencing: First comprehensive sequencing study of mesothelioma tumors published in 2016
• CDKN2A gender disparity: Deletions occur more frequently in male mesothelioma patients than in female patients
• CheckMate 743 impact: Nivolumab plus ipilimumab became the first immunotherapy combination approved for unresectable mesothelioma
• Successor timeline: Dr. Bueno assumed IMP leadership in 2018 following Dr. Sugarbaker's passing
• Active research areas: Immunotherapy combinations, targeted therapies, biomarker development, surgical timing optimization, and liquid biopsy monitoring
• Personalized treatment: Every IMP patient receives comprehensive genomic profiling before treatment planning begins

Related Pages

• Dr. David Sugarbaker
• Mesothelioma Molecular and Genetic Testing
• Clinical Trials
• Pleural Mesothelioma
• Mesothelioma Surgery Overview
• Pleurectomy and Decortication
• Mesothelioma Survival Statistics
• History of Mesothelioma Research
• Immunotherapy for Mesothelioma
• Mesothelioma Specialists

Get Help

If you or a loved one has been diagnosed with mesothelioma, accessing the latest treatment approaches—including the personalized medicine pioneered by Dr. Bueno at the International Mesothelioma Program—can significantly impact outcomes. You may also be entitled to compensation from the companies responsible for your asbestos exposure.

For a free legal consultation, contact the mesothelioma attorneys at Danziger & De Llano at (866) 222-9990. You can also find experienced attorneys through Mesothelioma Lawyers Near Me or explore patient resources at Mesothelioma.net.